
# Introduction High-flow oxygen therapy delivered through tracheostomy (HFTO) is used for oxygenation, heated humidification, secretion management, ventilator weaning, and decannulation. Its effects depend on flow, tracheostomy interface, cuff status, and the expiratory pathway, while pediatric evidence is poorly defined. # Methods We conducted a PRISMA-ScR-guided scoping review of adult and pediatric HFTO evidence. MEDLINE/PubMed, Embase, Scopus, Web of Science, and CINAHL were searched from inception through June 30, 2026 without age or database-level language restrictions. Adult evidence was included as a comparator to define pediatric evidence gaps. # Results Of 487 records identified, 319 remained after deduplication; 134 underwent full-text/full-record assessment, 99 were excluded, and 35 sources were included (32 completed and 3 ongoing trial/protocol records). Adult flows were commonly 40-60 L/min, with experimental settings of 10-80 L/min; the pediatric simulation used 5-30 L/min. Several adult studies reported improved oxygenation, whereas others found no change; effects on work of breathing, carbon dioxide clearance, airway pressure, and lung volume were variable. Safety reporting was inconsistent. Direct pediatric evidence was limited to one infant/toddler aerosol-delivery simulation. # Discussion HFTO is an interface-dependent respiratory therapy rather than a tracheostomy equivalent of nasal high-flow therapy. Cuff status, speaking-valve configuration, expiratory patency, flow, humidification, and treatment purpose should be reported explicitly. Adult feasibility cannot be assumed to establish pediatric effectiveness or safety. # Conclusion HFTO is feasible but incompletely defined. Standardized reporting of flow, interface/cuff configuration, humidification, monitoring, adverse events, secretion outcomes, and pediatric-specific clinical outcomes is needed.
# Background This systematic review and meta-analysis aimed to evaluate the clinical efficacy of mechanical insufflation-exsufflation (MI-E) compared with usual care in mechanically ventilated critically ill adults. # Methods We searched Embase, MEDLINE via PubMed, CINAHL, and the Cochrane Library for randomized controlled trials (RCTs) published up to April 2026 that compared MI-E with usual care in mechanically ventilated adults. The primary outcome was duration of mechanical ventilation. Secondary outcomes included the amount of aspirated airway secretions, respiratory system compliance, airway resistance, length of ICU stay, and mortality. Meta-analysis was performed when at least two studies provided clinically and methodologically comparable data. The certainty of evidence was assessed using the GRADE approach. # Results Six RCTs involving 492 participants were included. For the primary outcome of mechanical ventilation duration, only one RCT contributed to the effect estimate (MD, −2.67 days; 95% CI, −6.91 to 1.57; very-low-certainty evidence). MI-E increased the amount of aspirated airway secretions compared with usual care (MD, 1.47 g; 95% CI, 0.74 to 2.19; very-low-certainty evidence). No statistically significant differences were observed in respiratory system compliance or airway resistance. ICU length of stay also showed no difference (2 RCTs; MD, −1.75 days; 95% CI, −4.61 to 1.10; very-low-certainty evidence). Mortality was evaluated by one RCT (risk ratio, 1.56; 95% CI, 0.44 to 5.50; very-low-certainty evidence). # Conclusions The effects of MI-E on clinical outcomes in mechanically ventilated critically ill patients remain uncertain because the available evidence is of low to very low certainty. MI-E may improve airway secretion clearance; however, evidence regarding mechanical ventilation duration, ICU length of stay, and mortality remains very uncertain. Further high-quality randomized controlled trials are required.
# Introduction Pulmonary rehabilitation (PR) improves exercise capacity, functional status, and health-related quality of life in patients with chronic obstructive pulmonary disease (COPD). However, these benefits often decline over time, necessitating repeated PR. Evidence regarding the effectiveness of repeated PR on clinical outcomes remains limited. This study evaluated the effects of a second PR program on functional, physical, and patient-reported outcomes in patients with COPD. # Methods Data from patients with COPD who completed two PR programs (PR1 and PR2) at Ciro, Horn, the Netherlands, between January 2005 and September 2022 were retrospectively analyzed. Outcomes included exercise capacity (constant work rate test [CWRT]), quadriceps muscle strength (isokinetic quadriceps strength [IQS]), functional capacity (6-minute walk distance [6MWD]), and patient-reported outcomes using the COPD Assessment Test (CAT), St. George’s Respiratory Questionnaire (SGRQ), Hospital Anxiety and Depression Scale (HADS), and Canadian Occupational Performance Measure (COPM). # Results Of 7,984 PR records, 429 patients (858 PR records) met the inclusion criteria (54% men; mean age 62.5±8.1 years; FEV₁ 43.5% predicted). Significant improvements were observed following both PR programs, including 6MWD (PR1: Mean Difference \[MD\] 37.0 m, 95% Confidence Interval \[CI\] 29.2–44.8; PR2: MD 27.0 m, 95% CI 19.2–34.8) and IQS (PR1: MD 10.4 Nm, 95% CI 8.4–12.4; PR2: MD 8.6 Nm, 95% CI 6.6–10.6), as well as for CWRT, CAT, SGRQ, HADS, and COPM (all _p_ < 0.05). Improvements in 6MWD and IQS were significantly greater after PR1 than PR2 (_p_ < 0.05). All outcomes declined significantly between completion of PR1 and initiation of PR2 (_p_ < 0.05). # Discussion Although improvements following repeated PR were smaller than those after the initial program, clinically meaningful gains were achieved across multiple outcomes, supporting the value of repeated PR in patients whose health status deteriorates over time. # Conclusion Repeated PR effectively improves functional capacity, muscle strength, exercise performance, and patient-reported outcomes in patients with COPD. Strategies to sustain PR benefits after program completion should be prioritized.